FDA OKs Neuronetics’ OCD Therapy

Neuronetics has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its obsessive-compulsive disorder (OCD) Motor Threshold (MT) Cap tech for NeuroStar advanced therapy for mental health.
 
“This FDA clearance underscores our commitment to delivering the latest technology that will streamline the treatment process for our customers,” Cory Anderson, SVP of R&D and Clinical at Neuronetics, told the press. “The unique design and functionality of the OCD MT Cap will enable clinicians to optimize treatment efficiency while upholding the highest standard of care for their patients. This innovation also prepares NeuroStar for even further technological advancements expected later this year and next.”
 
According to Neuronetics, determining a patient’s MT is critical to establish the patient’s prescription before starting treatment. NeuroStar is the only transcranical magnetic stimulation (TMS) system with FDA clearance for MT Caps for both OCD and major depression.
 
The MT Cap simplifies initial NeuroStar coil placement by offering a consistent starting location and step-by-step process to map the motor cortex, shortening the time and reducing the number of steps needed. The OCD Cap, like the current MDD MT Cap, has compatibility with Fast MT to provide up to 40% time savings during the initial visit.
 
“The current MT Cap for depression became an immediate staple in my practice, and I have witnessed its numerous benefits firsthand. I am thrilled with the addition of the FDA-cleared MT Cap for OCD,” said Dr. Kenneth Pages, Medical Director at TMS of South Tampa. “This new technology is an important development, as it will further empower my practice to provide effective and personalized care for individuals struggling with OCD.”
 
The OCT MT Cap will become available at certain sites beginning this month. Neuronetics also released first of several TrakStar patient data management system software updates for NeuroStar earlier this year.